Wall Street brokerages expect IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) to announce earnings per share (EPS) of ($0.07) for the current quarter, Zacks reports. Three analysts have provided estimates for IntelliPharmaCeutics Intl’s earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.05). IntelliPharmaCeutics Intl posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is expected to announce its next quarterly earnings results on Friday, February 16th.
On average, analysts expect that IntelliPharmaCeutics Intl will report full year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.29) to ($0.24). For the next year, analysts forecast that the company will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.25) to ($0.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow IntelliPharmaCeutics Intl.
Several equities analysts have commented on IPCI shares. HC Wainwright set a $3.00 price target on shares of IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Monday. Maxim Group set a $2.00 price target on shares of IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, Zacks Investment Research upgraded shares of IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Wednesday, December 13th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. IntelliPharmaCeutics Intl currently has a consensus rating of “Hold” and an average price target of $2.53.
A hedge fund recently raised its stake in IntelliPharmaCeutics Intl stock. Advisor Group Inc. raised its stake in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,409 shares of the company’s stock after purchasing an additional 17,342 shares during the period. Advisor Group Inc. owned 0.16% of IntelliPharmaCeutics Intl worth $100,000 as of its most recent SEC filing. 3.28% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Brokerages Anticipate IntelliPharmaCeutics Intl Inc (IPCI) to Post -$0.07 Earnings Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/brokerages-anticipate-intellipharmaceutics-intl-inc-ipci-to-post-0-07-earnings-per-share.html.
About IntelliPharmaCeutics Intl
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.